4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): A randomised phase 3 non-inferiority trial

dc.contributor.authorMadhavan, K.
dc.date.accessioned2023-06-07T13:59:53Z
dc.date.available2023-06-07T13:59:53Z
dc.date.issued2014
dc.identifier.citationHoskin, P. J., Kirkwood, A. A., Popova, B., Smith, P., Robinson, M., Gallop-Evans, E., Coltart, S., Illidge, T., Madhavan, K., Brammer, C., Diez, P., Jack, A. & Syndikus, I. 2014. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): A randomised phase 3 non-inferiority trial. The Lancet Oncology, 15, (4) 457-463.
dc.identifier.doihttps://dx.doi.org/10.1016/S1470-2045%2814%2970036-1
dc.identifier.issn1470-2045
dc.identifier.issn1474-5488
dc.identifier.journalThe Lancet Oncology
dc.identifier.urihttps://hdl.handle.net/20.500.14265/1090
dc.language.isoEnglish
dc.publisherElsevier
dc.source.issue4
dc.source.pages457-463
dc.source.volume15
dc.title4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): A randomised phase 3 non-inferiority trial
dc.typeArticle
Files